PNH Is a Progressive and Life-Threatening Disease That Warrants Early Diagnosis and Intervention1-3
Evaluate high-risk patient populations for PNH
The PNH Diagnostic Pathway can help you identify patients at high risk for PNH, including those with aplastic anemia, myelodysplastic syndromes, and unexplained thromboses.
*Adapted from Parker, et al, Blood, 2005.
The life-threatening and destructive consequences of hemolysis (as measured by LDH) warrant early identification in these high-risk subpopulations
Chronic hemolysis is the underlying cause of progressive morbidities and mortality in PNH 6; therefore, reducing chronic hemolysis is the primary goal of PNH treatment.4,7 Early identification of PNH in high-risk populations is optimal for long-term disease management.
Early diagnosis drives effective PNH management4
If any of these conditions are evident in your patients, they should be tested for PNH4†
- Evaluate your patients with myelodysplastic syndromes (MDS) at diagnosis and your patients with aplastic anemia (AA) at diagnosis and annually4
- Many patients with AA or MDS go on to develop PNH
- The presence of even a very small number of PNH cells in patients with AA or MDS may be predictive of response to immunosuppressive therapy8,9
- Unexplained arterial (eg, transient ischemic attack [TIA]) or venous thromboses in typical (eg, DVT) or atypical sites4,10
- Coombs-negative hemolytic anemia4,10
- Hemolysis in the presence of anemia, fatigue, smooth muscle dystonia (dysphagia, abdominal pain, dyspnea, erectile dysfunction), unexplained visceral pain, or hemoglobinuria4,10
- End organ damage with hemolysis4,7
- Renal insufficiency
- Liver disease
†Adapted from Parker, et al, Blood, 2005.
Click on the following links for more information regarding diagnosis in populations at high risk for PNH: